Kristie H Lau

Ms. Kristie H Lau

California Northstate University College of Medicine
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KLKristie H Lau
Kristie H Lau
ATAlexandra M. Tan
Alexandra M. Tan
YSYihui Shi
Yihui Shi
In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including the expression of hormone receptors (estrogen receptor and/or progesterone receptor) and/or HER2. Primary breast cancer treatments can include surgery, radiation therapy, systemic chemotherapy, endocrine therapy, and/or targeted therapy. Endocrine therapy has been shown to be effective in hormone receptor-positive breast cancers and is a common choice for adjuvant therapy. However, due to the aggressive nature of triple-negative breast cancer, targeted therapy is becoming a noteworthy area of research in the search for non-endocrine-targets in breast cancer. In addition to HER2-targeted therapy, other emerging therapies include immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth. This review summarizes novel targeted breast cancer treatments and explores the possible implications of combination therapy.

31 May 2024 in American Journal of Infection Control
Verified
Journal Article
Closed access
EHElijah Huang
Elijah Huang
SKSiddharth Kurkure
Siddharth Kurkure
YSYui Seo
Yui Seo
KLKristie H Lau
Kristie H Lau
JPJosé Luis Puglisi
José Luis Puglisi